SYK Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 15.18% compared to Stryker's net margin of 11.12%. Stryker's return on equity of 18.78% beat Boston Scientific's return on equity of 8.91%.

Stryker has a consensus price target of $408.49, signalling upside risk potential of 11.71%. On the other hand Boston Scientific has an analysts' consensus of $100.72 which suggests that it could grow by 6.15%. Given that Stryker has higher upside potential than Boston Scientific, analysts believe Stryker is more attractive than Boston Scientific.

Stryker has a beta of 0.951, which suggesting that the stock is 4.874% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 35.99% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Boston Scientific quarterly revenues of $4.2B. Stryker's net income of $834M is higher than Boston Scientific's net income of $468M. Notably, Stryker's price-to-earnings ratio is 39.19x while Boston Scientific's PE ratio is 78.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.41x versus 8.84x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 15.18% compared to Stryker's net margin of 8.28%. Stryker's return on equity of 18.78% beat Globus Medical's return on equity of 2.27%.

Stryker has a consensus price target of $408.49, signalling upside risk potential of 11.71%. On the other hand Globus Medical has an analysts' consensus of $97.85 which suggests that it could grow by 12.38%. Given that Globus Medical has higher upside potential than Stryker, analysts believe Globus Medical is more attractive than Stryker.

Stryker has a beta of 0.951, which suggesting that the stock is 4.874% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 35.99% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Globus Medical quarterly revenues of $625.7M. Stryker's net income of $834M is higher than Globus Medical's net income of $51.8M. Notably, Stryker's price-to-earnings ratio is 39.19x while Globus Medical's PE ratio is 129.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.41x versus 4.82x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 15.18% compared to Stryker's net margin of 27.73%. Stryker's return on equity of 18.78% beat Intuitive Surgical's return on equity of 15.9%.

Stryker has a consensus price target of $408.49, signalling upside risk potential of 11.71%. On the other hand Intuitive Surgical has an analysts' consensus of $566.97 which suggests that it could grow by 3.56%. Given that Stryker has higher upside potential than Intuitive Surgical, analysts believe Stryker is more attractive than Intuitive Surgical.

Stryker has a beta of 0.951, which suggesting that the stock is 4.874% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.941%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 35.99% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Intuitive Surgical quarterly revenues of $2B. Stryker's net income of $834M is higher than Intuitive Surgical's net income of $565.1M. Notably, Stryker's price-to-earnings ratio is 39.19x while Intuitive Surgical's PE ratio is 88.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.41x versus 25.10x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Inari Medical has a net margin of 15.18% compared to Stryker's net margin of -11.97%. Stryker's return on equity of 18.78% beat Inari Medical's return on equity of -17.68%.

Stryker has a consensus price target of $408.49, signalling upside risk potential of 11.71%. On the other hand Inari Medical has an analysts' consensus of $74.12 which suggests that it could fall by -6.52%. Given that Stryker has higher upside potential than Inari Medical, analysts believe Stryker is more attractive than Inari Medical.

Stryker has a beta of 0.951, which suggesting that the stock is 4.874% less volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 35.99% of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.5B, which are larger than Inari Medical quarterly revenues of $153.4M. Stryker's net income of $834M is higher than Inari Medical's net income of -$18.4M. Notably, Stryker's price-to-earnings ratio is 39.19x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.41x versus 8.01x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.